Imuldosa (Ustekinumab)

Ustekinumab is a fully human monoclonal antibody that binds to the p40 subunit shared by interleukin‑12 and interleukin‑23. By preventing these cytokines from activating their receptors, the drug dampens Th1 and Th17 immune pathways, reducing inflammation that drives psoriasis, joint disease, and intestinal inflammation.

The dosing schedule for Imuldosa is individualized by the prescribing clinician based on factors such as patient weight, disease severity, prior treatment response, and specific label recommendations. Only a qualified healthcare professional should set the dose and infusion intervals.

Safety data for ustekinumab in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Clinicians should weigh potential benefits against possible risks and discuss options with the patient before initiating therapy.

To place an order, submit an enquiry on the Imuldosa product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling), and necessary import documentation.

Compared with tumor necrosis factor (TNF) inhibitors, ustekinumab targets a different cytokine pathway (IL‑12/23) and may be preferred in patients who have inadequate response or intolerance to TNF blockers. Its dosing interval is longer, which can improve convenience, but safety profiles differ, especially regarding infection and malignancy risks.

Imuldosa must be stored in a refrigerated environment between 2 °C and 8 °C. It should be kept in its original packaging, protected from light, and must never be frozen or shaken. If temperature excursions occur, the product should be inspected for visual changes before use.

Imuldosa is given as an intravenous infusion performed by a qualified healthcare professional. The initial dose is typically administered in a clinical setting, followed by subsequent infusions at intervals defined by the prescriber, often based on patient weight and therapeutic response.

The most serious adverse events include severe infections such as tuberculosis or opportunistic pathogens, the possible development of malignancies (e.g., lymphoma, skin cancers), and hypersensitivity reactions that can be life‑threatening. Patients should be monitored closely for signs of infection, new skin lesions, or allergic symptoms.

Imuldosa is contraindicated in individuals with known hypersensitivity to ustekinumab or any of its excipients. It should also be avoided in patients with active serious infections, untreated latent tuberculosis, or those who are pregnant or breastfeeding unless the potential benefit justifies the risk.